These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 32559844)
1. Combination therapy with SGLT2 inhibitors for diabetic kidney disease. Cai Y; Liu X; Xu G Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844 [TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Zou H; Zhou B; Xu G Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711 [TBL] [Abstract][Full Text] [Related]
3. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes. Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009 [TBL] [Abstract][Full Text] [Related]
4. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes. Bell DSH; Jerkins T Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874 [TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194 [TBL] [Abstract][Full Text] [Related]
7. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials. Lee MMY; Petrie MC; McMurray JJV; Sattar N Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025 [TBL] [Abstract][Full Text] [Related]
8. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Dougherty JA; Guirguis E; Thornby KA Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083 [TBL] [Abstract][Full Text] [Related]
9. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System. Poursharif S; Hamza S; Braam B Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506 [TBL] [Abstract][Full Text] [Related]
10. Impact of CVOTs in primary and secondary prevention of kidney disease. De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332 [TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589 [TBL] [Abstract][Full Text] [Related]
12. Combined effect of sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease. Araki SI J Diabetes Investig; 2020 Jan; 11(1):22-24. PubMed ID: 31520446 [No Abstract] [Full Text] [Related]
13. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Novikov A; Vallon V Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):50-8. PubMed ID: 26575393 [TBL] [Abstract][Full Text] [Related]
14. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145 [TBL] [Abstract][Full Text] [Related]
15. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028 [TBL] [Abstract][Full Text] [Related]
16. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. Alicic RZ; Johnson EJ; Tuttle KR Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460 [TBL] [Abstract][Full Text] [Related]
17. New Glucose-Lowering Agents for Diabetic Kidney Disease. de Vos LC; Hettige TS; Cooper ME Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579 [TBL] [Abstract][Full Text] [Related]
18. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337 [TBL] [Abstract][Full Text] [Related]
19. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326 [TBL] [Abstract][Full Text] [Related]
20. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning. Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074 [No Abstract] [Full Text] [Related] [Next] [New Search]